In this study, novel 2-substituted benzimidazoles molecules having triazole, thiadiazole, and oxadiazole rings were synthesized and were evaluated by anticancer, antioxidant/oxidant status, genotoxicity, and antiangiogenesis assays. Anticancer activity of the compounds was determined by MTT (0.5, 5, and 50 $\mu $g/mL) and lactate dehydrogenase (LDH) release assays against human prostate and breast cancer cells. Oxidative status of cells was elicited by total oxidative stress and total antioxidant capacity methods. Chick chorioallantoic membrane assay was used to evaluate the antiangiogenic activity. Genotoxicity was evaluated by the sister chromatid exchange (SCE) and micronucleus (MN) tests in lymphocyte cultured human blood. Our results showed that some of the compounds synthesized had significant antiproliferative activity against both cancer cell lines (between 4.54 $\pm $ 0.35 and 20.17 $\pm $ 3.15 $\mu $g/mL), with higher inhibition of the breast cancer, and caused inhibition of LDH release with a linear correlation to MTT results. Moreover, the 5 $\mu $g/mL dose of these molecules led to an increase in antioxidant levels. Compounds had antiangiogenic effectiveness in a dose-dependent manner. Additionally, all of the compounds did not affect SCE and MN levels compared to controls. In conclusion, these newly synthesized molecules can be a resource of new anticancer agents with their nongenotoxic, antiproliferative, and antiangiogenic properties.
在本研究中,合成了具有三唑、
噻二唑和恶二唑环的新型2-取代
苯并咪唑分子,并通过抗癌、
抗氧化剂/氧化状态、遗传毒性和抗血管生成测定进行了评估。通过M
TT(0.5、5和50μg/mL)和
乳酸脱氢酶(LDH)释放测定对人前列腺和乳腺癌细胞测定化合物的抗癌活性。通过总氧化应激和总抗氧化能力方法得出细胞的氧化状态。 使用鸡绒毛尿囊膜测定来评估抗血管生成活性。通过淋巴
细胞培养的人血中的姐妹染色单体交换(SCE)和微核(MN)测试评估遗传毒性。我们的结果表明,合成的一些化合物对两种癌
细胞系均具有显着的抗增殖活性(在 4.54 $\pm $ 0.35 和 20.17 $\pm $ 3.15 $\mu $g/mL 之间),对乳腺癌具有更高的抑制作用,并引起 LDH 释放的抑制,与 M
TT 结果呈线性相关。此外,这些分子的 5 $\mu $g/mL 剂量导致
抗氧化剂水平增加。化合物具有剂量依赖性的抗血管生成功效。此外,与对照组相比,所有化合物均不影响 SCE 和 MN
水平。总之,这些新合成的分子具有非
基因毒性、抗增殖和抗血管生成特性,可以成为新型抗癌药物的资源。